Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 4Uterine Neoplasms 1HER2/Neu Negative 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Magnetic Resonance Spectroscopy 5Specimen Handling 4Biopsy 3Steroids 2Hormones 2Cyclin-Dependent Kinase Inhibitor p18 2Cyclin-Dependent Kinase Inhibitor p16 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1taxane 1radium Ra 223 dichloride 1pertuzumab 1naxitamab 1eicosapentaenoic acid ethyl ester 1eicosapentaenoic acid ethanolamide 1binimetinib 1abemaciclib 1X-Rays 1Trastuzumab 1Taxoids 1Taxes 1Radiotherapy 1Radiosurgery 1Radiation 1Photons 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Mastectomy, Simple 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anatomic Stage IV Breast Cancer AJCC v8 × 16-fluoroestradiol × 1 year × Clear all
NCT07112053 2026-04-06

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

University of Washington

Phase 2 Recruiting
40 enrolled
Breast

Anatomic Stage IV Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡